Top-News

MoonLake Immunotherapeutics Aktie News

Aktie
WKN:  A3DFA7 ISIN:  KY61559X1045 US-Symbol:  MLTX Branche:  Biotechnologie Land:  Schweiz
14,90 $
-0,095 $
-0,63%
12,797 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
696,88 Mio. €
Streubesitz
16,75%
KGV
-28,65
Index-Zuordnung
-

MoonLake Immunotherapeutics News

07.10.25 - PR Newswire
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTX
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTX PR Newswire
06.10.25 - PR Newswire
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX PR Newswire
06.10.25 - PR Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm PR Newswire
03.10.25 - PR Newswire
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics PR Newswire
03.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake Immunotherapeutics - MLTX PR Newswire
02.10.25 - PR Newswire
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTX
Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action Investigation - MLTX PR Newswire
02.10.25 - PR Newswire
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm
MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm PR Newswire
02.10.25 - PR Newswire
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX
MoonLake Immunotherapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX PR Newswire
01.10.25 - PR Newswire
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman PR Newswire
28.09.25 - GlobeNewswire
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
VELA-1 and VELA-2 are two identical trials to evaluate the efficacy and safety of sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (HS) and the first ...
05.08.25 - GlobeNewswire
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic ...
12.05.25 - GlobeNewswire
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
25.04.25 - GlobeNewswire
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-...
03.04.25 - GlobeNewswire
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of ...
26.02.25 - GlobeNewswire
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Initiated the Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-​to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients ...
08.01.25 - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial ...

Newssuche

Videos

newspaper
06.12.25
Master the Trading!
In diesem Trading-​Webinar haben wir von A bis Z den Aufbau professionellen Tradings thematisiert und ... Mehr »